Takashi Matsuzaki

This study evaluates a bivalent Lassa virus mRNA vaccine in mice and guinea pigs, showing it provides complete protection against lethal infection, whereas monovalent vaccines do not.

This paper designs an engineered active zymogen of microbial transglutaminase (EzMTG) that exhibits cross-linking activity without requiring proteolysis, and identifies mutations that balance binding affinity and catalytic activity.